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The World Health Organization recommends the use of isoniazid preventive therapy to 
reduce the incidence of tuberculosis disease in populations at risk for developing the disease. 
Adherence to isoniazid preventive therapy is needful for efficacy. A urine assay known as the 
Arkansas test is widely used to monitor the ingestion of isoniazid. However, this test is 
limited by a drop in sensitivity with increasing time post isoniazid dose. Furthermore, results 
from the test can be affected by observer variation in colour changes, concomitant 
medications, urinary dilution, and presence of other substances in urine. Moreover, the 
Arkansas test results have not been evaluated against objective measurement of isoniazid and 
acetylisoniazid urine concentrations. This study seeks to measure the urine concentrations of 
isoniazid and acetylisoniazid at different time points after a dose in children, in order to 
establish reference ranges for liquid chromatography tandem mass spectrometry 
measurements of urine isoniazid and acetylisoniazid, as well as the Arkansas method. The 
reference ranges would provide a standard which can be used to estimate the probability of 
adherence to prior doses.   
Urine samples were collected from forty-one children on daily and intermittent isoniazid 
preventive therapy at different time points. Isoniazid and acetylisoniazid urine concentrations 
were determined using liquid chromatography tandem mass spectrometry measurements. 
Effect of age, weight, gender, dosing time, dosing frequency and urine creatinine on isoniazid 
and acetylisoniazid concentrations were evaluated. Arkansas test was carried out and results 
were evaluated using liqu d chromatography tandem mass spectrometry measurements of 
urine isoniazid and acetylisoniazid. 
Reference ranges for urine isoniazid and acetylisoniazid concentrations were established in 
the study population. No effect of age, weight, gender and dosing frequency was detected on 
isoniazid and acetylisoniazid urine concentrations. There was good agreement between 
Arkansas colour change and the concentrations of isoniazid and acetylisoniazid. Arkansas test 
is useful for monitoring adherence to 4 hours post isoniazid doses (prior to clinic attendance) 
in children on isoniazid preventive therapy. It is however not useful for monitoring adherence 
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In areas with high tuberculosis (TB) incidence, an important cause of morbidity and mortality 
in children is TB (Andvord, 2002; World Health Organization, 2008). Isoniazid Preventive 
Therapy (IPT) is recommended by World Health Organization (WHO) for children at risk of 
developing TB disease as a strategy to control and prevent tuberculosis (TB) (World Health 
Organization). For efficacy and to prevent the development of resistance, there is a need for 
adherence to therapy. The different methods used to monitor and assess adherence to IPT 
including self-reports, pill counts, electronic monitoring devices and urine assays all have 
their limitations (Perry et al., 2002). 
The Arkansas test method, a colorimetric method, is widely used to monitor the intake of 
isoniazid (INH). It identifies the presence of INH and its metabolites in urine. Results from 
the test can however be affected by factors such as observer variation in interpretation of 
colour changes, interference from concomitant medications, presence of other substances in 
urine, urine dilution and a major limitation of the test is a decrease in sensitivity with increase 
in time post INH dose. Previous studies on European adult populations showed sensitivity of 
greater than 90% up to 24 hours post INH dose and similar sensitivity was only achieved up 
to 12 hours post dose in black African adult population (Hanifa et al., 2007; Schraufnagel et 
al., 1990). The Arkansas test result however, has not been evaluated against objective 
measurement of INH and acetyl INH (AcINH) urine concentrations. 
This study seeks to measure the urine concentrations of INH and AcINH at different time 
points after a dose in children, in order to establish reference ranges for liquid 
chromatography tandem mass spectrometry measurement of INH and AcINH, as well as the 
Arkansas methods. The reference ranges will provide a standard which can be used to 
estimate the probability of adherence to prior doses. 
1.1 AIM 
 
To establish clear reference ranges of urinary INH in the study population.  
1.2 OBJECTIVES 
 
1. To evaluate INH urine concentrations of children who have been on daily dosing and 
intermittent dosing for prophylaxis at different time points using mass spectrometry 
















2. To evaluate effect of age, weight, dosing time and frequency, and urine creatinine (a 
marker of urine dilution) on urine INH/AcINH concentrations. 
3. To compare concentrations of INH and AcINH with the colour changes using 
Arkansas method at different times and frequency of dosing. 
4. To propose a cut-off Arkansas colour for adherence to last dose for the 4, 24, 48 and 

















2. LITERATURE REVIEW 
 
2.1 TUBERCULOSIS (overview) 
 
TB is a transmissible bacterial infection which affects the lungs primarily (pulmonary TB), 
but can also be disseminated to other parts of the body (extra pulmonary TB) including the 
skin, bones, nervous system, digestive and urogenital tracts, lymph nodes through the blood 
stream and lymphatic system (Kumar et al., 2012; Mitchell et al., 2007). The disease is 
caused by Mycobacterium tuberculosis (M. tuberculosis) which was first identified and 
described by Robert Koch in 1882 (Huebner et al., 1993; Nobel Foundation, 1905). As 
estimated by WHO in 2010, a third of the world’s population is infected with the organism 
(World Health Organization, October 2012). WHO reported an estimate of 8.7 million new 
cases of TB and 1.4 million deaths in 2010 (World Health Organisation, 2011). The 
worldwide distribution is shown in figure 1.1. Majority of the population in many Asian and 
African countries test positive to tuberculin tests while with the United States, only 5 – 10% 
of the population test positive (Kumar et al., 2012; Mitchell et al., 2007). 
 



















M. tuberculosis is transmitted by air droplets when people, usually adults with active 
pulmonary TB disease, cough, sneeze, laugh or spit (Lawn et al., 2011; Van Soolingen et al., 
1997). Those who are latently infected are thought to be non-infectious (Kumar et al., 2012). 
Transmission occurs when droplet containing M. tuberculosis is inhaled and transverse the 
mouth or nasal passages, upper respiratory tract and bronchi to reach the lungs’ alveoli (CDC, 
2011a). 
M. tuberculosis transmitted to children can become latent or develop to pulmonary, 
disseminated or severe forms of TB disease including TB meningitis, and miliary TB. Young 
age and human immunodeficiency virus (HIV) infection are the most important risk factors 
for severe or disseminated TB disease (Marais et al., 2004; Nelson et al., 2004). 
2.1.2 LATENT TB INFECTION AND ACTIVE TB DISEASE 
 
TB infection in children could be seen as covering the spectrum from recent infection with M. 
tuberculosis, before an immune response is mounted, to an established state of equilibrium 
(Seddon et al., 2012). In latent TB, the cells of the immune system which includes 
macrophages, T lymphocytes, B lymphocytes and fibroblasts aggregate to form granulomas 
with lymphocytes surrounding the infected macrophages. The granuloma prevents 
dissemination and growth of the mycobacteria. This makes the infection inactive with no 
symptoms and in a situation that can persist for years. However, it can reactivate and progress 
to disease in some people, especially in the setting of diminished immunity (Grosset, 2003).  
The active disease occurs when the immune system is too weak to stop bacterial growth and 
the bacteria invade and replicate within endosomes of alveolar macrophages in the lungs. 
Active disease when developed requires prompt diagnosis and treatment to prevent spread of 




















Table 1 Characteristics of latent TB infection and TB disease. Adapted from (Bass Jr et al., 1990).  
Latent TB infection TB disease 
Result of skin or blood test usually indicates TB 
infection. However, there may be false positive 
results. 
 
Result of skin or blood test usually indicates TB 
infection. There may however  be false negative 
results 
Chest X-ray may or may not be normal. Sputum test is 
usually negative 
Abnormal chest X-ray or positive sputum smear or 
cultures 
 
Infected individual does not feel sick Individual usually feels sick and may have symptoms 
such as coughing, fever and weight loss 
 
Individual cannot spread TB bacteria to others Individual with respiratory or pulmonary disease can 
spread TB bacteria to others 
 
Treatment of  latent TB infection prevents progression 
to TB disease 
 
Needs treatment of TB disease 
   
2.1.3 SIGNS, SYMPTOMS AND DIAGNOSIS OF TB 
 
Signs and symptoms of TB disease include a chronic unremitting cough, weight loss or 
failure to thrive, fever, fatigue, loss of appetite, unexplained pneumonia. A definitive 
diagnosis of TB is made by identifying M. tuberculosis bacteria in a clinical specimen taken 
from the patient (CDC, 2011b). In children, it is often not possible to bacteriologically 
confirm TB and diagnosis is frequently made on a composite of history, clinical and 
immunological grounds (Khan et al., 1995; World Health Organization, 2006). Investigations 
such as immunological tests (Mantoux tuberculin skin test), chest radiography, computed 
tomography scans are used also in diagnosis. The tuberculin skin test (TST) (Huebner et al., 
1993) is the primary screening test for the diagnosis of latent TB. In this test, purified protein 
derivative (PPD), a material derived from M. tuberculosis is injected into the skin of an 
individual and the reaction on the skin as indicated by the degree of induration is evaluated 
after about 48-72 hours (Huebner et al., 1993). A person is said to be positive to the TST 
(PPD positive) if there is a strong skin reaction. TST is positive in HIV-infected children if 
induration is 5 mm or greater while an induration less than 5 mm is said to be TST negative 
(Huebner et al., 1993). A positive TST is an indication of TB infection (recent or latent). In 
children, TB diagnosis is a challenge due to the limitations of the TST and Mycobacterial 
















2.1.4 RISK FACTORS FOR TB 
 
Those at high risk for developing TB disease include: 
 HIV-infected individuals - HIV infection is the most powerful factor that predisposes 
an individual to progress from latent TB to the active disease (Corbett et al., 2003). 
The lifetime risk of progression from latent TB infection to active disease is about ten 
percent in the general population and five to fifteen percent yearly in HIV-infected 
persons with the risk increasing as immune deficiency worsens (Aaron et al., 2004).  
People co-infected with HIV and TB are about 21-34 times more likely to develop TB 
disease compared with those who are HIV-uninfected  (World Health Organization, 
2011). In high prevalence areas, the risk of developing TB disease in children less 
than 5 years has been shown to be 3.5 times higher than in adults (Van Rie et al., 
1999). Though the risk of TB declines after 2 years of age, children with severe 
malnutrition and HIV infection, especially those with severe immune suppression 
remain at high risk of TB (Moyo et al., 2010). Up to 25% of South African children 
with HIV infection develop TB annually if they are not on antiretroviral treatment 
(ART) (Martinson et al., 2009; Zar et al., 2007). While ART reduces the incidence of 
TB in children, the risk remains higher than in HIV-uninfected children (Marais et al., 
2006). HIV-infected children have been shown to have higher mortality than those 
who are HIV-uninfected when they develop TB (Walls et al., 2004). 
 Children and babies in contact with TB patients are at risk for developing TB. In high 
prevalence areas, the risk of developing TB disease in children less than 5 years has 
been shown to be 3.5 times higher than in adults (Van Rie et al., 1999). Young 
children or children with impaired immunity frequently experience severe forms of 
TB including disseminated disease and meningitis. 
 Elderly people (Stead et al., 1983).  
 Patients receiving certain medication treatments such as anti-cancer chemotherapy, 
corticosteroids, transplant anti-rejection medication. 
 Individuals born where TB is prevalent such as in Africa, Asia, Latin America. 
 Individuals exposed to TB through their jobs such as health care workers. 
 People who inject illicit drugs (Graham et al., 1992; Perlman et al., 1995). 
















2.1.5 PREVENTION OF TB 
 
Prevention of TB relies on satisfactory adherence to the treatment regimen by people with 
infectious TB, vaccination of children in TB prevalent countries, and TB preventive therapy 
in persons infected with HIV (Lawn et al., 2011).  The bacilli Calmette Guerin (BCG) 
vaccine is currently given to babies at birth as part of the routine vaccine schedule 
particularly in countries where TB is highly prevalent (McShane, 2011). The vaccine has 
been reported to confer variable protection against contracting pulmonary TB and immunity 
decreases after about ten years, however, it is thought that it offers some protection against 
developing extra pulmonary TB (Lawn et al., 2011; McShane, 2011). BCG vaccine has been 
reported to offer a protective estimate of 73% (range 67% - 79%) against TB meningitis and 
77% (range 58% - 87%) against miliary disease in children (Trunz et al., 2006). 
2.1.6 TREATMENT OF TB 
 
Treatment of most forms of pulmonary and extrapulmonary TB requires a minimum of six 
months with multiple anti-TB medications, usually four drugs (INH, rifampicin, ethambutol 
and pyrazinamide) in the intensive phase and two drugs (INH and rifampicin) in the 
continuation phase (Swaminathan et al., 2010). The drugs mentioned above are first-line anti-
TB drugs. Second-line drugs are used when situations like resistance to first-line therapy, 
multidrug-resistant TB (MDR-TB) or extensively drug-resistant TB (XDR-TB) arise. They 
include aminoglycosides, polypeptides, fluoroquinolones, thioamides, and cycloserine. 
(Caminero et al., 2010; Goldman et al., 2007; Shah et al., 2007). Third-line drugs  include 
macrolides, thioacetazone (Hari et al., 2010; Rajeev et al., 2011). Single drugs are used only 
in latent TB or chemoprophylaxis. The use of single drug for treatment of active disease 
results in the rapid development of resistance and treatment failure (Committee, 1948; Wang 
et al., 2006). The different drugs in the TB regimen have different modes of action which is a 
reason for their combination.  
2.2 ISONIAZID 
 
Isoniazid (INH) is an important drug in the treatment of TB and the only medication 
approved by World Health Organization (WHO) for TB preventive therapy (World Health 
Organization, 2011). The drug has powerful bactericidal activity against metabolically active 
















Absorption: When taken orally, it is well absorbed from the gastrointestinal tract. In patients 
co-infected with TB and advanced HIV disease, there is concern that HIV may reduce anti-
TB drug concentrations however; there exist limited evidence to this in children.  
Distribution: INH is readily distributed throughout the body (Greenberg et al., 1962). It 
diffuses into all body tissues and fluids including cerebrospinal fluids, breast milk and saliva 
(Kucers et al., 1979). It is not appreciably bound to plasma protein. 
Elimination: INH is eliminated mainly by metabolism. The primary route is acetylation by 
N-acetyl transferase enzyme found in the liver and small intestine (Weber et al., 1979). INH 
is trimodally eliminated. The rate of elimination is determined by genetic polymorphisms of 
the arylamine N-acetyl transferase 2 gene (Parkin et al., 1997). Schaaf et al. taking into 
account the N-acetyl transferase 2 enzyme showed that younger children eliminate the drug 
faster than older children and as a group, faster than adults (Schaaf et al., 2005). In children 
less than 13 years given 10 mg/kg INH, Schaaf reported elimination rate constants (per hour) 
of 0.254, 0.513 and 0.653 for homozygous slow, heterozygous fast and homozygous fast 
acetylators from INH concentrations obtained at 2, 3, 4 and 5 hours post INH dose which was 
higher than those of adult patients given a similar 10 mg/kg INH dose. N-acetyl transferase 2 
genotype is a determinant of INH concentrations in adults and children (Parkin et al., 1997; 
Schaaf et al., 2005). Studies involving children aged 3 months to 13 years with slow, 
intermediate and fast genotypes  given variable INH doses (from <4 to > 12 mg/kg) showed  
peak concentrations (Cmax)  of 4.05, 2.63 and 1.54 mg/L respectively (McIlleron et al., 2009). 
Very little of INH is excreted unchanged in urine and the greater proportion is acetylated to 
AcINH. AcINH is hydrolysed to isonicotinic acid and monoacetyl hydrazine. Isonicotinic 
acid conjugates with glycine to give isonicotinyl glycine while monoacetyl hydrazine 
undergoes further acetylation to give diacetyl hydrazine. Some of the unmetabolised INH 
conjugates to alpha-ketoglutarate and pyruvate to hydrazones (Hughes et al., 1955). Figure 2 
















Figure 2 Flow chart showing elimination products of INH. Adapted from (Hughes et al., 1955).  
75-90% of INH is excreted in the urine within 24 hours mainly as metabolites. INH is 
generally well tolerated by children but rarely, hepatic t xicity, neurologic and 
gastrointestinal side effects may occur (Feja et al., 2005).  
2.3 TREATMENT OF LATENT TB INFECTION (TB PREVENTIVE 
THERAPY)  
 
TB preventive therapy involves the use of anti-TB drugs singly or in combinations to prevent 
progression of latent TB infection to active disease. A meta-analysis was carried out using 
randomized controlled trials in which HIV-infected participants were randomly allocated to 
different regimens to assess the effect of preventive therapy on the incidence of TB and 
reduction of mortality. The different regimens compared were: 
- Any anti-TB drug versus placebo 
- INH + rifampicin versus placebo 
- Rifampicin + pyrazinamide versus placebo 
- INH + rifampicin + pyrazinamide versus placebo 
Any anti-TB drug versus placebo reduced the risk of active TB by 32% (RR 0.68 95% CI 
0.54 – 0.85). This effect was seen more in individuals with a positive TST (RR 0.38, 95% CI 
0.25-057) than in those with a negative test (RR 0.89 95% CI 0.64-1.24). Efficacies for all 
regimens were alike but INH monotherapy stood out (Akolo et al., 2010). Unlike other short 
course multidrug regimens, it was less associated with discontinuation of therapy due to 















a reduction in mortality however, overall, there is no evidence that TB preventive therapy 
reduces mortality significantly (Akolo et al., 2010). 
2.3.1 INH PREVENTIVE THERAPY  
 
IPT, intensified case finding and infection control form the 3 I’s strategy of WHO to reduce 
the burden of TB among people living with HIV. IPT utilizes INH alone for patients infected 
with HIV to prevent the incidence of TB when active TB has been excluded (Cotton, 2011). 
Use of INH for TB preventive therapy has been known to reduce the incidence of TB in high 
risk individuals for over forty years (Comstock et al., 1967; Ferebee et al., 1963). Trials of 
treatment for latent TB infection conducted by Ferebee and colleagues in the 1960’s 
established that INH administered for six to nine months was effective in preventing TB in 
adults and children with latent TB (Ferebee, 1970). Treatment of latent TB reduces the risk of 
developing active TB in HIV-infected individuals especially those with a positive TST 
(Akolo et al., 2010). Studies suggest that IPT is protective in adults receiving antiretroviral 
therapy (ART) (Golub et al., 2009; Golub et al., 2007) and reduces TB incidence in HIV-
infected adults (Bucher et al., 1999; Grant et al., 2005; Mwinga et al., 1998; Pape et al., 
1993; Whalen et al., 1997; Wilkinson et al., 1998).  
With good adherence, INH chemoprophylaxis was effective in preventing progression to 
disease in 69 – 93% of infected children (International Union Against Tuberculosis 
Committee on Prophylaxis, 1982). A double-blind study carried out by Zar and colleagues in 
Cape Town to assess the value of universal IPT in HIV-infected children prior to or in the 
absence of documented exposure to a source case showed a benefit in mortality comparing 
INH with placebo (11 (8%) versus 21 (16%) ) (HR 0.46 95% CI 0.22-0.95, P=0.015). The 
incidence of TB was also lower in the INH group (5 cases, 3.8%) than in placebo (13 cases, 
9.9%) (HR 0.28 95% CI 0.10-0.78, P=0.005) (20). Another study by Madhi and co-workers, 
a large multi-centre trial of 548 HIV-infected and 804 HIV-uninfected infants between 3-4 
months of age in South Africa and Botswana showed no benefit of pre-TB exposure IPT 
when compared with placebo in reducing the incidence of TB and mortality (Madhi et al., 
2011). The disparity could be explained by difference in patient population and access to 
ART. Recently, an additive benefit of IPT and ART has been reported in HIV-infected 
children after 5 years of follow up. INH reduced the risk of TB disease by 0.22 (95% CI 0.09 















INH plus ART reduced the risk of TB disease by 0.11 (95% CI 0.04 – 0.32) (Frigati et al., 
2011). 
2.4 RECOMMENDATIONS FOR IPT IN CHILDREN 
 
WHO recommends IPT for six months in children living with HIV, greater than twelve 
months of age, unlikely to have active TB on symptoms based screening and have no contact 
with a TB case as part of a comprehensive package of HIV prevention and care service 
(World Health Organization, 2011). 
In children with HIV who are less than twelve months of age, only those who have contact 
with a TB case and are evaluated for TB (using investigations) should receive six months of 
IPT if the evaluation shows no TB (World Health Organization, 2011). 
All children living with HIV who have successfully completed treatment of TB disease 
should receive INH for an additional six months (World Health Organization, 2011). 
IPT is recommended in South Africa for HIV-infected children and all children less than 5 
years of age (regardless of HIV status), after exposure to a source case (Cotton, 2011).  
2.5 ADHERENCE AND ASSESSING ADHERENCE TO IPT  
 
Sub-optimal adherence and non-adherence in TB prevention and control are common 
important issues in people living with HIV and other populations at high risk of developing 
TB. Adherence on one hand is difficult because patients are asymptomatic, feel well, the 
dosing regimen is prolonged and medications can produce side effects (Ailinger et al., 2008). 
Also, most people on IPT are already on other ARV’s therefore increasing the burden of pills 
being taken. On the other hand, people already taking ARV’s might be more adherent since 
once they have the habit of taking their medications, it could enhance their adherence 
compared to someone whose only medication is INH.  Limited data exist on adherence to 
treatment and chemoprophylaxis regimens in children in settings highly burdened by TB 
(Van Zyl et al., 2006). However, adherence to IPT has been reported to be poor in different 
populations at risk and studies have shown non-adherence rates to be  8 - 44.2% (Szakacs et 
al., 2006; Van Zyl et al., 2006). Van Zyl et al. reported that adherence to anti-TB treatment in 
children less than five years of age was significantly better than adherence to 
chemoprophylaxis (82.6% versus 44.2%, p<0.001) and that adherence to unsupervised 















efficacy of therapy. Monitoring, to detect non-adherent patients, would allow for prompt 
counselling to be offered to the non-adherent patients identified. 
There is no gold standard for assessing adherence (Starr et al., 1999). Frequently used 
methods are discussed below alongside their limitations. They include self-reports/caregiver 




Many studies assessing patients’ compliance to IPT use self-reports as a means of measuring 
adherence. Self-reports are cheap, easy to obtain and do not demand as much labour as some 
other methods. It could also give valid adherence reports (Blumberg et al., 2005)  however, it 
is not completely reliable as it can be affected by forgetfulness and social desirability bias 
(Starr et al., 1999). In a study that compared self-reports and other methods for monitoring 
adherence to IPT, self-reporting appeared to overestimate adherence (Starr et al., 1999). In 
children where caregiver reports are depended upon, assessing self-report can be a challenge 
when children arrive with different caregivers for study visits (le Roux et al., 2009).  
2.5.2 PILL COUNTS 
 
Pill counts rely on patients remembering to bring left over tablets to the clinic. In one of the 
few trials to perform pill counts regularly, they showed an association between good 
adherence defined as taking more than 80% of doses on each monthly visit and treatment 
efficacy (International Union Against Tuberculosis Committee on Prophylaxis, 1982). A 
limitation of this method is that it could give false adherence measures as patients could 
manipulate left over tablets (Starr et al., 1999). In children, caregivers sometimes have to 
repeat medication doses when a child vomits, spits out the medicine or there is spillage and 
this can lead to overestimation of adherence (le Roux et al., 2009). 
2.5.3 USE OF ELECTRONIC MONITORING DEVICE 
 
This measures adherence indirectly and depends on data obtained from electronic device in a 
container lid that records the date and time container was opened (Ailinger et al., 2008; le 
Roux et al., 2009). The best correlation between measures of adherence and treatment effect 
has been shown with these devices in patients with hypertension or diabetes (Cramer, 2004). 















especially when they had a prior knowledge that information would be obtained from the lid 
cover or less often than required like taking out pills for more than one dose (Ailinger et al., 
2008; Starr et al., 1999). Other limitations include technical problems which could also occur 
when using electronic monitoring devices and high cost of device (Ailinger et al., 2008). 
2.5.4 URINE ASSAYS 
 
The sure way to establish the intake of a drug is by demonstrating its presence or that of its 
metabolites in a body fluid such as urine, saliva or blood (Ellard et al., 1980). This can be 
done either quantitatively or qualitatively but unlike quantitative methods, qualitative 
methods only reflect recent drug ingestion and do not quantify or differentiate parent 
compounds and their metabolites (Sirgel et al., 2006). Quantitative methods on the other hand 
are expensive, labour intensive and require a well-equipped laboratory with trained personnel 
(Sirgel et al., 2006). Tandem mass spectroscopy with high performance liquid 
chromatography because of its sensitivity and specificity is a rapidly growing method for 
analysis of drug in different matrices but it is impractical for continuous monitoring of 
adherence (Ng et al., 2007). Urine assays are non-invasive and are most suitable for 
compounds which are polar since the concentrations in urine are likely to be higher than 
concomitant salivary levels (Ellard et al., 1980). 
To monitor the ingestion of INH, urine tests are easily applicable, inexpensive, non-invasive 
and collection of urine samples is acceptable by patients and parents (Palanduz et al., 2003). 
These make it easy to frequently perform urine tests and possibly use it for evaluating 
compliance. The drawbacks however are that the tests do not give information about dose 
ingested, demonstrates only recent drug intake and does not necessarily reflect overall 
adherence  (Palanduz et al., 2003; Starr et al., 1999). Also, urine test samples may be diluted 
due to excessive intake of fluids close to sample collection time or concentrated due to 
decreased fluid intake. Creatinine concentration is checked during standard urine drug tests to 
know if test sample is diluted or not. 
2.5.4.1 URINE CREATININE 
 
Creatinine is a metabolic by-product of muscle metabolism (Karriem-Norwood, 2012). It is 
chiefly filtered out of the blood by the kidneys with little or no tubular reabsorption, and is 
passed out of the body in urine in relatively constant quantities over a 24 hour period with 















using a urine creatinine test which measures the amount of creatinine in the urine as an 
indicator of urine water content or as a marker identifying a specimen as urine. Greater than 
normal intake of water will increase the urine water content (lowering the creatinine level) 
consequently diluting the amount of drug in urine. Conversely, a limited intake of water can 
lead to an abnormally concentrated urine specimen (as occurs with dehydration) resulting in 
elevated creatinine levels. Urine creatinine test can be done alone or with other tests that 
determine the relative amounts of other substances being excreted in the urine. Random urine 
creatinine levels have no standard reference ranges. Normal random urine creatinine 
concentrations range from 40-300 mg/dL in males and 37-250 mg/dL in females (Redwood 
Toxicology, 2013). In pharmacokinetic studies, concentration of the drug relative to the 
creatinine is used as a way to standardize measurement and account for the problem of 
varying dilution due to varying intake of fluids by the individual.  
2.6 QUALITATIVE URINE TESTS  
Different qualitative urine tests have been developed to monitor intake of INH. A method for 
detecting N-AcINH in urine was described by Eidus and Hamilton (1964). A more sensitive 
method for determination of INH metabolites- isonicotinic acid and isonicotinylglycine was 
reported by Ellard and Greenfield. The method could be used for urine samples collected 
from about 1-24 hours from patients ingesting 300 mg of INH daily (Ellard, 1977). Kilburn 
reported the use of reagent impregnated strip to detect the presence of isonicotinic acid and 
isonicotinylglycine using potassium thiocyanate, chloramine-T and barbituric acid (1972). 
Currently, a frequently used test is the Arkansas test. 
2.6.1 ARKANSAS TEST  
 
The Arkansas test is a widely used urine test which objectively identifies the presence of INH 
and its metabolites in urine (Perry et al., 2002). It was developed by Potts, Cozart and Reagan 
and later reported by Henderson (Schraufnagel et al., 1990). It is simple, quick, inexpensive, 
reliable and gives immediate visual results that can be easily read which makes it useful in 
evaluating drug compliance in patients being treated for latent TB infection with a single 
daily dose of INH (Eidlitz-Markus et al., 2003). With its repeated use as a follow up method, 
it could be useful in better characterizing adherence (Guerra et al., 2010; Perry et al., 2002). 
Reagents utilised for the test are readily obtainable and have a shelf-life of at least six months 















change with positive tests varies (Guerra et al., 2010; Hanifa et al., 2007; Schraufnagel et al., 
1990). Colours which have been reported as positive include dark blue or turquoise, blue, 
purple, blue-green, green (Hanifa et al., 2007; Palanduz et al., 2003; Schraufnagel et al., 
1990). White, yellow, orange, light lemon and no colour change have been reported for 
negative results. These colours were read at variable times; Schraufnagel reported 
development of colour within two minutes, other studies read colours at times ranging from 
1-30 minutes (Guerra et al., 2010; Hanifa et al., 2007; Perry et al., 2002). Those which 
utilised dipstick and other devices that contained the reagents took longer times to read 
developed colours. 
The Arkansas test has been validated in different populations and has been reported to have 
high sensitivity and specificity. Schraufnagel reported a sensitivity and specificity greater 
than 97% and 98% respectively (Schraufnagel et al., 1990). A sensitivity/specificity of 
>95%/98% was reported by Renata and colleagues in the fifth minute when an isoscreen 
utilizing Arkansas method was used to measure adherence to IPT in an outpatient hospital 
population 24 hours post INH observed dose. In this study, there was a difference in the 
sensitivity of the test when colour changes were read at the first and fifth minutes with the 
fifth minute having a higher sensitivity than the first minute (84% and 95%; first and fifth 
minute) however, specificity remained the same (Guerra et al., 2010). Hanifa and colleagues 
reported sensitivities of 93.4% (95%CI 88.2-96.8) at 12 hours and 77% (95%CI 69.1 - 83.7) 
at 24 hours post INH dose in a black African adult male population. Lower sensitivity at 24 
hours post dose than those reported by other studies was thought to be due to a higher 
proportion of fast acetylators in the black African population (Hanifa et al., 2007). 
Factors that could affect the Arkansas test result include: 
1) Misinterpretation of colour changes on which the test is based particularly when test 
produces a weak colour. Objectively evaluating concentrations with colours produced 
from the Arkansas test would help to establish a cut-off for defining a positive or 
negative result as well as, value for telling about last dose (few hours before visit) or 
dose prior to that. 
2) Concomitantly administered medications; one study reported a pink colour result in a 
single urine sample when INH and aspirin were concomitantly administered (Kilburn 
et al., 1972). Another study also reported a pink colour in a single urine sample when 















3) Presence of other substances in urine such as nicotine. 
4) Variability in the amount of INH metabolites in urine (Ellard et al., 1980). 
5) Natural background colour of the urine sample (Ellard et al., 1980). 
6) Inaccuracies inherent with the test. 
A major limitation of this test is that sensitivity drops with increasing time post INH dose 
making it difficult to know a patient who has not been compliant for even a few days (Hanifa 
et al., 2007; Szakacs et al., 2006). Sensitivities of greater than 90% have been reported at 
post INH ingestion times less than or equal to 12 hours and even up to 24 hours in European 
populations (Hanifa et al., 2007; Kilburn et al., 1972; Schraufnagel et al., 1990). Lower 
sensitivities of 76% and 85% were reported by Elizaga and Perry respectively at 48 hours 
post INH dose (Elizaga et al., 1997; Perry et al., 2002). Perry and colleagues utilized recall 
interval to validate the Arkansas test which can be limited by forgetfulness. This study 
validates the Arkansas method by evaluating it against objective measurement of INH and 
AcINH urine concentrations particularly in children. The method chosen for the 
quantification of INH and AcINH in this study is the High Performance Liquid 
Chromatography tandem Mass spectrometry. The technique is described below. 
2.7 HIGH PERFORMANCE LIQUID CHROMATOGRAPHY TANDEM 
MASS SPECTROMETRY (HPLC-MS/MS) 
 
2.7.1 HIGH PERFORMANCE LIQUID CHROMATOGRAPHY  
 
High performance liquid chromatography (HPLC) is used to separate a mixture of 
compounds with the purpose of identifying, purifying and quantifying the individual 
components of the mixture. It involves the introduction of the sample mixture to be separated 
into a column containing sorbents (also known as stationary phase). The individual 
components of the mixture are moved through the column at different velocities by a liquid 
forced through the column by high pressure (this technique is also called high pressure liquid 
chromatography). The interaction (chemical/physical) between the molecules of the sample 
mixture and the stationary phase aids in the separation of the components. The different 
components of the sample are then identified by a detector at the end of the column base on 
the time each component reaches the detector after injection. The intensity of each 
component is measured by the detector and the end result is presented as a chromatogram as 
















Figure 3 HPLC chromatogram of the flavonoid and phenolic acid standards at 280 nm. Peaks: 
1=gallic acid; 2=gentisic acid; 3=(+)-catechin; 4=chlorogenic acid; 5=caffeic acid; 6=(-)-epicatechin; 
7=p-coumaric acid; 8=sinapic acid; 9=benzoic acid; 10=p-anisic acid; 11=myricetin; 12=3,4,5-
trimethoxycinnamic acid; 13=quercetin. Reprinted from (Chen et al., 2001).  
2.7.2 MASS SPECTROMETRY (MS) 
 
This is an analytical technique that measures the mass-to-charge ratio of charged particles. It 
is a technique with the ability to provide elemental analysis and molecular weight of a 
compound, and it can also be used to identify various fragments of a molecule (Snyder et al., 
2011). The method of operation can be explained using the diagram in figure 4. 
 
















After a sample is introduced in to the source, the sample is vaporised (if not in gaseous state) 
since mass spectrometry requires freely moving atoms or molecules. An electron beam 
ionises the sample forming charged particles. 
Analyser 
In the analyser, an electromagnetic field separate the ions by their mass-to-charge ratio. 
Using the measure of the particle, only ions of the right mass are allowed into the detector. 
Ion detector 
The abundance of each mass is detected by varying the magnetic field. 
Data system 
Finally, the ion signal is processed and a mass spectrum is given as an output. 
All samples that are to be analysed using MS must first be separated before it is inputted. If 
mixtures are not separated, the output will be a spectral of overlapping peaks. For this reason, 
a technique such as HPLC that separates mixtures into its various components can be used in 
tandem with MS/MS. 
2.7.3 HPLC-MS/MS 
 
The use of the sensitive ability of HPLC in tandem MS/MS (selective ability) (Matuszewski 
et al., 2003) can be applied to samples requiring high sensitivity and selectivity. It is a 
technique that is being used in various fields. Some investigators have used this technique to 
detect traces of illicit drugs (Berset et al., 2010; Boleda et al., 2007; Zuccato et al., 2008). It 
has been used to quantify and identify different collagen types (Pataridis et al., 2009), and its 
sensitivity, selectivity and precision for the study of nine environmental phenols in urine 
using automated online column switching system has been shown (Ye et al., 2005). Recently 
it has been used to quantify INH and AcINH in plasma with excellent precision and accuracy 
with calibration curves exhibiting linearity within a range of 1 – 250 ng/ml of INH and 0.05 – 
50 ng/ml of AcINH (Ng et al., 2007). In this study, it is used to quantify INH and AcINH in 

















3. STUDY POPULATION AND METHODS 
 
3.1 SETTING AND PARTICIPANTS 
 
This study is embedded in a large IPT study in an established research facility at Red 
Cross War Memorial Children’s Hospital (RCCH), University of Cape Town. Children 
who were participating in the main study, aged sixteen years and below, HIV-infected 
on ARVs and randomized to receive daily or intermittent (thrice weekly) doses of INH 
or placebo as prophylaxis were eligible to participate in the study. Parents or legal 
guardians had already given a full written consent to participation in the main study and 
study was approved by the Faculty of Health Sciences Human Research Ethics 
Committee (HREC ref no. 299/2005). The ethics committee also approved a review of 
the main study for extra urine sampling. Caregivers gave a verbal informed consent. 
Caregivers and children were offered some form of compensation for their time and 
transport fare. 
Assays were conducted in an established research laboratory which is recognized 
internationally for TB, HIV and Malaria outputs and is accredited by South African 
National Accreditation System (an internationally recognized agency for the 
development of and conduct of HPLC-MS/MS assays on biological samples). 
3.2 STUDY PROCEDURES 
 
The study pharmacist generated a list of children who had been allocated to INH or 
placebo from the main study, distributed between the two regimens (daily and thrice 
weekly INH or placebo in a dose of 8-12 mg/kg depending on whether a quarter or half 
a tablet was required) in a ratio of three to one (3:1) for INH: placebo. The rest of the 
study team (including those who read the colours observed from the colorimetric assay) 
remained blinded with respect to allocation of INH or placebo. A case record form 
(CRF) and standard operating procedures (SOP) were designed for data capturing and 
sample collection on the clinical site.  
Appointments were made with caregivers of study participants who were reminded in 
advance by the study nurse of the scheduled sampling visit day(s). The study nurse 
contacted the participants’ caregivers during the week of the urine sampling date to 















of urine sampling; to record the exact time and dose of the last dose of INH/placebo 
and any other drug taken within the last two days prior to sampling; not to give child 
any drug before arrival on the day of urine sampling. 
At visit, the following information were gathered: weight, height, date of birth of the 
study participant, concomitant medications, time of last meal before dose at visit, 
whether or not child vomited after dose of INH and time of vomit. 
Dose administration and urine sampling: 
In the intermittent arm, children were asked to come once on a Monday when they 
would have had their doses approximately 72 hours earlier (on a Friday) and urine 
samples were collected on arrival. Then they ingested a dose in the clinic (under the 
observation of a nurse) and 4 hours later, urine samples were taken. The same patients 
were asked to come on a Wednesday which would be approximately 48 hours after the 
dose taken at the clinic and again, urine samples were taken on arrival.   
In the daily arm, children were asked to come once on a Wednesday when they would 
have had their doses approximately 24 hours (on a Tuesday) and urine samples were 
collected on arrival. They then ingested a dose in the clinic (under the supervision of a 
nurse) and 4 hours later, urine samples were taken. 
INH dose prior to clinic visit (dose before 72 hours and 24 hours urine sampling) was 
given by child’s caregiver. Adherence to this dose was maximized through caregiver 
phone call. Time and dose taken was verified and recorded by the study nurse. INH 
dose at clinic visit (dose before 4 hours and 48 hours urine sampling) were observed by 
the study nurse. 
4-hour time point for urine collection was chosen because it is a typical time after dose 
for children attending clinic visits. 
The exact dates, days and times (to the nearest minute) of sampling (time urine sample 
was presented) were recorded on the case record form. 
Duplicate urine samples (each 1ml) were pipetted into appropriately labelled eppendorf 
tubes, placed in a suitable cool box with dry ice and on the same day transferred with a 
sample inventory form for each sample to the pharmacology laboratory at Groote 















AcINH concentrations determination and Arkansas testing. The rest of the urine sample 
collected was decanted into tubes, labelled and sent to the RCCH chemical pathology 
laboratory for urine creatinine measure. 
3.3 LABORATORY METHODS 
 
3.3.1 COLORIMETRIC DETERMINATION OF INH AND AcINH METABOLITES 
IN URINE 
 
The Arkansas test was carried out according to the procedure described by 
Schraufnagel (1990). 30 mg of barbituric acid was weighed into tubes. This was 
followed by the addition of 140 µL of urine, 70 µL of chloramine T (14 g/dl) used 
within one hour of preparation and 70 µL of potassium cyanide (5 g/dl). The test tubes 
were agitated vigorously by hand and allowed to stand for 10 minutes. Photographs of 
colour produced by each sample were then taken in a white box with the camera and 
test tube positions approximately uniform for each sample. Two observers initially read 
the colours independently in a subset of the data which included 48 samples. Range of 
colours reported included dark blue, blue, violet, green, light blue, pale blue, green, and 
yellow but because of the excellent concordance between observers and limited 
resources, a subsequent decision to rationalize to one observer was made.   Colours 
were read by comparing photographs taken with a colour chart and recorded. The test 
was carried out on samples in batches of 10. 
Control samples for HPLC-MS/MS assay were obtained by spiking urine (obtained 
from individuals who were not taking INH) with INH and AcINH. The dilutions were 
carried out as stated below and the limit of quantification for INH and AcINH obtained. 
200 µL was pipetted from 1 mg/ml INH in methanol into a clean tube. 4.8 ml of urine 
was then added to it to make 5 ml solution containing 40 µg/ml INH. Other dilutions 
were done with the equations shown below. 
1 ml of 40 µg/ml INH + 1 ml urine → 20 µg/ml INH 
1 ml of 40 µg/ml INH + 3 mls urine →10 µg/ml INH 
1 ml of 40 µg/ml INH + 7 mls urine → 5 µg/ml INH 















1 ml of 5 µg/ml INH + 4 mls urine → 1 µg/ml INH 
1 ml of 1 µg/ml INH + 1 ml urine → 0.5 µg/ml INH 
1 ml of 0.5 µg/ml INH + 1 ml urine → 0.25 µg/ml INH 
1 ml of 0.25 µg/ml INH + 1mls urine → 0.125 µg/ml INH 
1 ml of 0.125 µg/ml INH + 1 ml urine → 0.0625 µg/ml INH 
1 ml of 0.0625 µg/ml INH + 1 ml urine → 0.03125 µg/ml INH 
1 ml of 0.03125 µg/ml INH + 1 ml urine → 0.015625 µg/ml INH 
Similar dilution as above was also carried out for AcINH. The limit of quantitation was 
0.125 µg/ml for both INH and AcINH. 
3.3.2 DETERMINATION OF INH AND ACINH BY HPLC-MS/MS  
 
INH and AcINH were analyzed using an HPLC/MS/MS based assay. Urine samples were 
centrifuged to remove any particulate matter and then diluted tenfold with water.  10 µL was 
injected onto the column.  Gradient chromatography was performed on a Phenomenex, Luna 
5 μm PFP(2), 100 A, 50 mm  2 mm analytical column, using acetonitrile and 5 mM 
ammonium acetate as mobile phase, and was delivered at a flow rate of 300 µl/min.  An AB 
Sciex API 3200 Q-Trap mass spectrometer was operated at unit resolution in the multiple 
reaction monitoring (MRM) mode, monitoring the transition of the protonated molecular ions 
at m/z 131 to the product ions at m/z 121 for INH and the protonated molecular ions at m/z 
180 to the product ions m/z 138 for INH.  The calibration range for both compounds was 
between 0.125 µg/ml and 20 µg/ml. 
HPLC-MS/MS conditions were as follows: 
Curtain gas:  25  
Ion spray voltage:  5500 
Temp:  500 °C 
 Gas 1:  50 















Declustering potential for INH:  31 
Declustering potential for AcINH:  66 
 Collision energy for INH:  25 
 Collision energy for AcINH:  31 
The standard curves used to extract the concentrations from peaks produced by the mass 
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3.4 STATISTICAL ANALYSIS 
 
Based on the distribution of the data which was examined and showed non-normal 
distribution, it was summarized as median and interquartile range (IQR). The nonparametric 
Wilcoxon rank-sum test was used to determine whether the 4-hour urine concentrations for 
the daily and intermittent arms where statistically significantly different. Univariate 
regression analysis was used to determine the association between covariates and urine 
concentrations of INH and AcINH. Quantile regression analysis was used to measure the 
increase in urine concentrations of INH and AcINH for each unit increase in urine creatinine. 
Regression analysis was also used to measure the increase in the urine concentrations of INH 
and AcINH, respectively, for each colour compared to colour 1 (the reference). Analysis was 

















4.1 PATIENT CHARACTERISTICS 
 
A total of 41 children; 22 females, 19 males with median age 7.7 years (IQR, 6.6 - 9.5 years)               
were selected for the study. 24 were on daily and 17 on intermittent dosing schedules. 31 
children participants received prophylactic INH and 10 placebo. Of the 31 children who 
received INH, 18 received it daily and 13 intermittently. 
Each of the 24 children on daily dosing schedule submitted a 4-hour and 24-hour urine 
sample. 16 of the intermittent arm children submitted all three 4, 48 and 72 hours’ urine 
samples. The 17th child could not submit a 72-hour urine sample because her caregiver could 
not make it to any of the Monday’s urine sampling schedule. Altogether, 36 samples from the 
INH daily arm and 38 samples from the INH intermittent arm were assayed. Of these, 46 
were from female children and 28 from male children. The results from children taking 
placebo were excluded in the final analysis as they all showed negative for both colorimetric 
and mass spectrometry assays. The age and weight (median (IQR)) for children whose 
samples were used in analysis was 7.7 years (IQR, 6.1-8.5 years) and 21.3 kg (IQR, 17.2 - 
28.8 kg) respectively. The characteristics of the children and number of samples produced are 
summarized in table 2.  
Table 2 Patient characteristics. 
Characteristics Daily Intermittent Total 
Gender    
Male 13 6 19 
Female 11 11 22 
Median age (years) 
 
7.65 7.7 7.7 
Number of children on 
INH 
18 13 31 
Number of children on 
placebo 
6 4 10 
Number of samples 
collected at 4 hours 
18 13 31 
Number of samples 
collected at 24 hours 
18 - 18 
Number of samples 
collected at 48 hours 
- 13 13 
Number of samples 
collected at 72 hours 
- 12 12 
Number of samples used 
for analysis 















The participating children were on other medications and this was noted. The different 
medications used concomitantly with the INH medication and the number of patients on each 
medication are shown in table 3. All the children that participated in this study were on 
Antiretroviral drugs and a few were taking multivitamin concomitantly with INH but no pink 
colour result was seen from the Arkansas test on those samples like previously reported by 
Hanifa (2007). 
Table 3 Concomitant medications used by study population. 
Concomitant drug No. of patients 









Sodium valproate 3 
Cotrimoxazole 3 
Vitamin B complex 7 




4.2 ARKANSAS TEST RESULTS 
 
The Arkansas test results were available for all the samples. For the INH group (children on 
prophylactic INH), several colours were observed which includes dark blue, blue, light blue 
violet, light blue, pale blue/green and yellow. All samples from the children randomized to 
placebo showed a yellow colour or no colour change with the Arkansas test. Previous studies 
have reported similar colours; Schraufnagel et al reported dark blue for positive and yellow 
for negative (1990), Hanifa (2007) and Schmitz (2010) reported blue and green colours for 
positive while yellow and no colour change were considered negative. The colours observed 

















Table 4 Table showing Arkansas test colours observed and their codes. 
Colour observed Codes 
Yellow/no colour change 1 
Pale blue/green 2 
Light blue 3 
Light blue violet 4 
Blue 5 
Dark blue 6 
 
Fig. 7 is the colour chart used to read the colours and Fig. 8 shows representative photographs 
of the Arkansas test result on clinic samples.  
 
Figure 7 Colour chart used for the Arkansas test. 
 
Figure 8 Representative clinic samples showing colours produced by the Arkansas test. 
Figures 9 and 10 are bar charts showing the frequency of the different colours produced by 
the Arkansas test for the daily and intermittent arms at the different sampling times. For the 
daily arm, blue, dark blue and light blue violet were the predominant colours at 4 hours, 
while yellow, pale blue/green and light blue were the more common at 24 hours. Light blue 
colour was seen in two 4-hour samples even though the concentrations of INH and AcINH 
were high (concentrations were similar to other 4-hour samples). One yellow colour and one 















hours sample also showed yellow colour. The pale green colour at 4 hours came from a child 
whose 24 hours sample showed yellow.  
In the intermittent arm, light blue violet, blue and dark blue were the predominant colours 
observed at 4 hours which is similar to that of the daily arm. No light blue and pale 
blue/green colours were observed and only one sample showed yellow at 4 hours. At 48 
hours, yellow was the predominant colour with the other colours observed as pale blue/green 
(2 samples) and light blue (1 sample). None of the predominant colours (dark blue, blue and 
light blue violet) at 4 hours was observed at 48 hours. Only yellow or no colour change was 
observed for all the 72 hours samples.  
 
Figure 9 Bar chart showing colours observed from the Arkansas test and their frequencies of 









































Figure 10 Bar chart showing colours observed from the Arkansas test and their frequencies of 
occurrence at 4, 48 and 72 hours sampling times in the intermittent arm. 
There was a transition in the observed colours with increasing time post INH dose as shown 
in figure 11. In figure 11, darker colours (dark blue, blue and light blue violet) were only 
observed up to 24 hours post INH dose. At 48 hours post INH dose, only pale colours (pale 
blue and pale green) and predominantly yellow colours were observed. At 72 hours, only 







































Figure 11 Scatter plot showing transition in Arkansas colour with increase in sampling time. 
 
4.3 HPLC-MS/MS RESULTS   
 
INH and AcINH urine concentrations were available for all the samples and are summarized 
and shown in table 5. The concentrations of INH and AcINH decreased with increase in time 
(4 hours to 72 hours) post INH dose (INH median concentration; 133.50 – 0.00 µg/ml, 
AcINH median concentration 116.00 – 0.00 µg/ml). At 4 hours, median concentration of INH 
was higher than that of AcINH but with increase in time post INH dose, median 
concentration of AcINH became higher than that of INH as shown in table 5.  
Table 5 Urine INH and AcINH concentrations by HPLC-MS/MS at different sampling times, in daily 
and intermittent dosing schedules, for INH preventive therapy. 






INH ACINH INH + ACINH 
4 31 133.50 (45.75 – 273.00) 116.0 (36.05 – 272.00) 298.5 (112.25-536.0) 
24 18 0.53 (0.34 – 4.90) 3.91 (1.39 – 9.95) 4.43 (1.67-18.8) 
48 13 0.00 (0 – 0.20) 0.22 (0 – 0.37) 0.22 (0.14-0.54) 
















For INH, 1 sample obtained at 4-hour, 1 sample obtained at 24-hour, 7 samples obtained at 
48-hour and 3 samples obtained at 72-hour points were below the limit of quantification for 
HPLC-MS/MS measurement carried out. Similarly, 1 sample obtained at 24-hour, 2 samples 
obtained at 48-hour, and 1 sample obtained 72-hour points for AcINH were below the limit of 
quantification. These samples whose concentrations fell below the limit of quantification 
were assigned a value of zero for the concentration.  
Figures 12 and 13 show the urine concentrations for INH and AcINH respectively at each 
sampling times while figure 14 shows the combined urine concentrations of INH and AcINH 
at each sampling time.  
 
Figure 12 INH urine concentrations at each sample collection time in 31 children on INH preventive 
therapy. Horizontal bars in boxes represent median concentration, whiskers represent minimum and 
















Figure 13 AcINH urine concentrations at each sample collection time in 31 children on INH 
preventive therapy. Horizontal bars in boxes represent median concentration, whiskers represent 
minimum and maximum concentrations, boxes represent 25th and 75th percentiles.
 
Figure 14 INH + AcINH urine concentrations at each sample collection time in 31 children on INH 
preventive therapy. Horizontal bars in boxes represent median concentration, whiskers represent 















Two samples from a child (15.9 years old) in the daily INH arm showed no levels for both 
INH and AcINH (both produced yellow colour for Arkansas test) at 4 and 24-hour time 
points and a 4-hour sample from a child (4.9 years) in the daily arm had low concentrations 
of 0.2 µg/ml and 2.07 µg/ml for INH and AcINH (pale green colour) respectively. A 4-hour 
sample from a child in the intermittent arm had a concentration of 0.352 for AcINH and for 
INH, concentration fell below the limit of quantification (yellow colour for Arkansas test). A 
48-hour urine sample from a child showed light blue colour for Arkansas test with high 
concentrations of 137 µg/ml and 26.87 µg/ml for INH and AcINH respectively. These are 
more in line with 24 to 72-hour time points and recent ingestion of INH on the morning of 
urine collection and could be considered as outliers. It is likely these children with very low 
urine INH and AcINH concentrations did not take the dose at the allocated time (even though 
the doses were supposed to be observed) and the child with very high concentrations had his 
drug in the morning before coming to the clinic. 
 No significant effect of age, dose, weight and gender was detected on urine concentrations of 
INH and AcINH by univariate regression analysis. Urine creatinine was seen to be 
significantly associated with INH and AcINH concentrations by regression analysis (P<0.001 
for both INH and AcINH). There was a 9.68 µg/ml (95% CI 4.51 – 14.84 µg/ml) change in 
INH concentration and 7.04 µg/ml (95% CI 4.96 – 9.12 µg/ml) change in AcINH 
concentration for each unit increase of creatinine. A plot of INH and AcINH urine 

















Figure 15 Plot of INH urine concentration against urine creatinine. 
 
Figure 16 Plot of AcINH urine concentration against urine creatinine. 
 
There was no statistically significant difference between the urine concentrations of INH and 















139.25 (18.30 – 273.00) µg/ml versus 122.00 (51.50 – 255.00) µg/ml for intermittent arm, 
p=0.8175; and AcINH, median (IQR) for daily arm 102.75 (36.05 – 227.00) versus 216.50 
(69.00 – 421.00) µg/ml for intermitent arm, p=0.5165). 
4.4 COMBINED ARKANSAS AND HPLC-MS/MS RESULTS 
 
Figures 17, 18 and 19 show concentrations of INH, AcINH and a combination of INH and 
AcINH respectively for the different colours produced by the Arkansas test. 
In figures 17 and 18, there was an increase in median concentrations of INH and AcINH as 
colour moved from yellow to dark blue. The unit increase in concentrations of INH and 
AcINH between each colour and yellow and their 95% CI values are shown in tables 6 and 7. 
For INH, the increase in median concentration was not seen between the light blue violet 
(colour code 4) and blue (colour code 5).  Although we were unable to measure urine 
concentrations of other metabolites of INH, urine concentrations of INH and AcINH 
correlated with the different shades of blue colour produced by the Arkansas test by 
multivariate regression analysis (INH: R
2
=0.4423, p<0.0005; AcINH: R
2
=0.4606, p<0.005).  
 
 
Figure 17 Box plot showing concentrations of INH for each Arkansas colour produced. The numbers 

















Figure 18 Box plot showing concentrations of AcINH for each Arkansas colour produced. The 
numbers 1 to 6 represent colours from yellow to dark blue as shown in Fig. 7. 
 
 
Figure 19 Box plot showing concentrations of INH+AcINH for each Arkansas colour produced. The 
numbers 1 to 6 represent colours from yellow to dark blue as shown in Fig. 7. 















Table 6 Table showing unit increase in concentration of INH between each colour and yellow for the 
Arkansas test and their 95% CI. 






0.32 -73.31 – 73.95 
Light blue 
 
99.67 15.20 – 184.10 
Light blue violet 
 
172.80 96.17 – 249.30 
Blue 
 
110.60 39.50 – 181.80 
Dark blue 
 
267.10 190.50 – 343.70 
 
 
Table 7 Table showing unit increase in concentration of AcINH between each colour and yellow for 
the Arkansas test and their 95% CI. 






1.70 -127.20 – 130.60 
Light blue 
 
26.44 121.40 – 174.30 
Light blue violet 
 
138.20 4.09 – 272.20 
Blue 
 
233.50 109.00 – 358.00 
Dark blue 
 
465.70 331.60 – 599.80 
 
The proportion of samples with detectable INH and AcINH on HPLC-MS/MS, and the 
proportion with a positive Arkansas test (dark blue, blue, light blue violet, light blue, pale 




















Table 8 Proportion of positives for Arkansas test and mass spectrometer measures of INH and 
AcINH. 
 Daily Intermittent 
 4 hr 24 hr 4 hr 48 hr 72 hr 
 n = 18 n = 18 n = 13 n = 13 n = 12 
Arkansas positivity, % 94.1  (17) 77.8 (14) 92.3 (12) 23.1 (3) 0 (0) 
% with detectable INH 
(HPLC-MS/MS) 
94.1  (17) 94.1 (17) 92.3 (12) 30.8 (4) 25 (3) 
% with detectable 
AcINH (HPLC-MS/MS) 
94.1  (17) 94.1 (17) 100 (13) 69.2 (9) 41.7 (4) 
Figures in parenthesis represent the number of samples that tested positive and n represents the total number of 
samples.  
 
From table 8, the Arkansas test gave similar positive proportion result to the mass 
spectrometer urine concentration measures at 4 hours post INH dose in the daily arm 
(94.1%). Proportion in the daily arm would have been 100% if results from the child’s 
samples which showed negative for the Arkansas test and zero urine concentrations for INH 
and AcINH were excluded. The decrease in proportion for the intermittent arm (92.3% 
against 100%) was caused by a single sample which showed a yellow colour with low levels 
of INH and AcINH, 0 and 0.352 µg/ml respectively (these concentrations and colour 
observed are more in line with 24 to 72-hour time points). 
At 24, 48 and 72 hours post dose, the proportions of positives for the Arkansas test dropped 
to 77.8%, 23.1% and 0% respectively. The proportions of positives were lower than those 
obtained from the mass spectrometric measurements as shown in table 8.  
To determine an optimal cut-off Arkansas colour for adherence to last dose for each of the 4, 
24, 48 and 72-hour time points, results from the Arkansas test and HPLC-MS/MS were used 
to draw a table under the following conditions: 
1) The 4-hour results for the daily and intermittent arms were combined. 
2) Proportions of positives for all samples are designated P1. In a secondary analysis with 
results designated P2, few outliers were excluded (outliers are reported in section 4.3). 
For the results taken as outliers, mass spectrometer measurements of INH and AcINH 
did not reveal that those children actually had their drugs before the 4 hours urine 
















3) Using the colour code in table 4, break points for each colour was defined in the 
following way; if a colour was chosen as negative, then colours with a higher number 
in the colour-code table were regarded as positive. All samples that fall in colours 
regarded as positives were then used to calculate the proportion of positives using that 
break point.  
4) Since the results used for the table came from children in the INH group (children on 
daily or intermittent INH), the cut-off point which gave the highest proportion of 
positives was then considered the optimal cut-off Arkansas colour.   
Table 9 shows the proportions of positives for different Arkansas colours and time points.  
Table 9 Table showing the proportion of positives for different Arkansas colours and time points. P1 
represent proportion of positives for all samples and P2 represent proportion without outliers. 
 
Proportion of positives (%) 
 
                Time 
Break point 
4 hours 24 hours 48 hours 72 hours 
Y    –   PB/G 
(-)         (+)                        
P1    93.5 
P2  100.0 
P1     77.8 
P2     82.4 
P1      23.1 
P2      16.7 
P1        0.0 
P2       0.0 
PB/G  -  LB 
(-)         (+) 
P1    90.3 
P2  100.0 
P1       38.9 
P2     41.2 
P1       7.7 
P2       0.0 
P1       0.0 
P2       0.0 
LB  -   LBV 
(-)         (+) 
P1     83.9 
P2    92.9 
P1       16.7 
P2     17.6 
P1         0.0 
P2       0.0 
P1        0.0 
P2        0.0 
LBV -  B 
(-)         (+) 
P1     58.1 
P2    64.3 
P1       11.1 
P2     11.8 
P1       0.0 
P2       0.0 
P1        0.0 
P2        0.0 
B   -   DB 
(-)       (+) 
P1      29.0 
P2       32.1 
P1       0.0 
P2       0.0 
P1       0.0 
P2       0.0 
P1          0.0 
P2        0.0 
DB 
(-)     
P1      0.0 
P2      0.0 
P1         0.0 
P2       0.0 
P1       0.0 
P2       0.0 
P1        0.0 
P2        0.0 
Y=yellow, PB/G=pale blue/green, LB=light blue, LBV=light blue violet, B=blue, DB=dark blue. (+)=positive, 
(-) =negative. 
At 4 hours with outliers, no 100% proportion of positives was obtained with any of the break 
points. However, similar proportions (93.5% and 90.3%) were obtained for yellow - pale 
blue/green and pale green/blue – light blue break points. Without the outliers, 100% 
proportion was obtained when yellow - pale blue/green and pale blue/green – light blue break 
points. With the similar proportions of positives obtained with yellow - pale blue/green and 
pale blue/green-light blue chosen as breakpoints, pale blue colour is chosen as cut-off for 















At 24 hours, proportions for yellow – pale blue/green colour was 77.8% (with outliers), 
82.4% (without outliers) and differed greatly when pale blue/green – light blue colour (with, 
38.9; without, 41.2%) was used as break point. 


















5. DISCUSSION AND CONCLUSION 
 
This study describes ranges of urine concentrations of INH and AcINH from 4 to 72 hours 
after the last dose in children on INH preventive therapy. The Arkansas test colour changes 
were evaluated using mass spectrometric measurements of INH and AcINH. Urine 
concentrations of INH and AcINH decreased with increasing time post INH dose as shown in 
table 5. There was an excellent correlation between colour change with the Arkansas test and 
the amount of INH, AcINH and INH plus AcINH respectively (figures 17 – 19 and tables 6 - 
7). A decrease in urine INH and AcINH concentrations coincided with the transition to paler 
colours with increasing time post INH dose as shown in figures 11 and 13. The decrease in 
concentrations could explain why the Arkansas test sensitivity for evaluation of last dose 
adherence declines with increase in time post INH dose although, the concentrations of other 
metabolites were not evaluated alongside. It is however expected that the concentrations of 
other metabolites also decrease with increase in time post INH dose since they are products 
of AcINH breakdown (Fig.2). 
The similar proportion of positives produced by the mass spectrometer and Arkansas test as 
shown in table 8 and the reduction from 100% caused by only single sample in each arm 
shows the Arkansas test to be reliable at 4-hour post INH dose and can be useful for 
monitoring ingestion of morning doses in children during clinic visits. The Arkansas test 
however, is not useful for monitoring 24-hour and above post INH doses ingestion. HPLC-
MS/MS is useful for monitoring up to 24-hour post INH dose ingestion but it is not useful at 
48-hour post INH dose (tables 8 and 9). A more sensitive mass spectrometer is required for 
48 hours and above (table 8). 
With the similar proportions of positives obtained with yellow - pale blue/green and pale 
blue/green – light blue chosen as breakpoints, pale blue/green colour was chosen as optimal 
cut-off Arkansas colour for adherence to 4 hours post INH dose (table 6). However, there is 
need to confirm findings in larger rigorously conducted study. 
The dark blue Arkansas colour seen only with the 4-hour urine samples and not with the other 
time points is useful in telling that patient ingested his drug in the morning (approximately 4 
hours) before coming to the clinic (although urine concentrations of other metabolites were 
not determined in this study, also background urine colour might have an impact on the 















For the samples that showed very low urine INH and AcINH concentrations (two 4-hour 
samples - one of the samples came from a child in the daily arm (age, 4.9 years; INH and 
AcINH concentrations, 0.2 µg/ml and 2.07 µg/ml respectively; urine creatinine, 4.8 mmol/L), 
the other sample was from a child in the intermittent arm (age, 8.4 years; INH and AcINH 
urine concentrations, 0 and 0.352 µg/ml respectively; urine creatinine, 9.8 mmol/L)), there 
was no clear reason to why the urine concentrations were low. However, the children who 
produced these samples could possibly not have taken their drugs (since we did not strictly 
observe the doses), have impaired absorption or result may have been affected by their 
acetylator status. HIV infection could cause the impaired absorption of anti-TB drugs which 
can lead to a significant reduction in urine levels of INH and AcINH (Gurumurthy et al., 
2004). Variability in acetylator status due to differences in intestinal and hepatic N-acetyl 
transferase 2 enzyme activity due to genetic polymorphisms can also affect INH 
concentration. 
In summary, I have addressed objectives 1 (To evaluate INH urine concentrations of children 
who have been on daily dosing and intermittent dosing for prophylaxis at different time 
points using mass spectrometry measurement of INH nd AcINH, and Arkansas method) and 
2 (To evaluate effect of age, weight, dosing time and frequency, and urine creatinine on urine 
INH/AcINH concentrations) for the study population. This however, should be confirmed in 
other populations which may be different for various reasons including N-acetyl transferase 2 
genotype which was not evaluated in this study. Moreover, a larger sample size may be 
required to detect the effects of the relevant covariates. I compared the concentrations of INH 
and AcINH with the colour changes using Arkansas method (objective 3) and found that 
there was good agreeme t between colour change and the concentrations of INH and an even 
stronger association with AcINH concentrations. Objective 4 (To propose a cut-off Arkansas 
colour for adherence to last dose for the 4, 24, 48 and 72-hour time points): pale blue/green 
colour was proposed for non-adherence to 4 hours post INH dose. However, possible non-
adherence within protocol could affect results. There is need to confirm findings in larger 
rigorously conducted study. None-the-less, my findings made a valuable contribution to the 
interpretation of adherence to INH doses using the Arkansas test.  While it can reliably detect 
a recent dose (4 hours after dose), 24 hours after the dose it does not perform well. More 
studies are needed to assess the proportion of positives for the test between dose and 4 hours 















In conclusion, ranges for INH and AcINH urine concentrations were obtained. The Arkansas 
test is useful in monitoring morning doses approximately 4 hours before clinic attendance of 
prophylactic INH in children. It can reliably detect a recent 4 hours after INH dose but does 

















5.1 STUDY LIMITATIONS 
 
A limitation to this study was our inability to strictly observe all the doses before urine 
sampling. Though we tried to optimize the use of phone calls to cover for this limitation, a 
few of the results may have been affected by non-adherence. 
Sample size was limited. A large sample size may be required to detect effects of the relevant 
covariates on INH and AcINH urine concentrations. 
A single observer read the colour which could create a strong chance of bias. However, the 
observer was blinded as to allocation of INH/placebo to reduce this bias. 
Acetylator status, known to be an important determinant of INH concentrations was not 
determined for study cohort. 
5.2 FURTHER WORK 
 
This study evaluated INH and AcINH concentrations in urine samples collected at 4, 24, 48 
and 72-hour time points. Further work is required to assess other time points between dose 
and 4-hour and later than 4-hour up to 12-hour (during which clinic visits might occur). 
Concentrations of INH and AcINH agreement with colour changes using Arkansas test 
should be confirmed in other populations which may be different for various reasons 
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